What Pro Doc Ltée does

Pro Doc Ltée is a Quebec-based, privately held generic pharmaceutical manufacturer that has been operating since 1955 and today employs 11-50 staff at its Laval, Quebec headquarters. The company produces approximately 300 prescription generic medications spanning cardiovascular (anticoagulants, statins, calcium channel blockers), central nervous system (anticonvulsants, neuropathic pain agents), anti-infectives (amoxicillin and combinations), antidiabetics (metformin), and gastrointestinal (proton pump inhibitors) therapeutic categories. Its products are bioequivalent to originator drugs, manufactured under Health Canada approval and rigorous quality controls on raw materials and finished products, and positioned as lower-cost alternatives enabled by the absence of medical-representation and large promotional spending.

Pro Doc generates revenue through one-time sales of these generic prescription products to community pharmacies across Quebec, distributing through its own field force of regional pharmaceutical representatives and an authenticated healthcare-professional portal that requires pharmacist or physician credentials for access. The company does not publicly disclose pricing; generic-pharmaceutical pricing is described as subject to government regulation and negotiated purchasing agreements. Distribution is structurally aligned with its corporate parent: Pro Doc has been a subsidiary of Groupe Jean Coutu since 2007 and is now part of METRO Inc.'s pharmacy division, alongside the Jean Coutu and Brunet retail pharmacy banners, providing captive shelf access across Quebec.

The business also operates supporting services including a pharmacovigilance/adverse-event reporting line with Health Canada regulatory escalation, bilingual (French/English) patient information leaflets, and a regional sales force covering every major Quebec administrative region. Pro Doc is not pursuing public listing, has no disclosed external funding, and serves the Canadian market only, with its website restricted to Canadian healthcare professionals. The combination of mature portfolio, parent-owned distribution, and Quebec-only footprint defines it as a stable, channel-anchored generic manufacturer rather than a growth-stage or technology-led business.

Name

Pro Doc Ltée

Legal name

Pro Doc Ltée

Website

https://prodoc.qc.ca

Company type

Private

Founded year

1955

Operating status

Operating

Headcount range

11–50 employees

Short description

Pro Doc Ltée is a Quebec-based generic pharmaceutical manufacturer (founded 1955) producing approximately 300 Health Canada-approved prescription generic drugs distributed to community pharmacies across Quebec. It is a wholly-owned subsidiary of METRO Inc., operating within its pharmacy division alongside the Jean Coutu and Brunet retail banners.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Generic pharmaceuticals
• Prescription medications
• Drug manufacturing
• Community pharmacy
• Pharmaceutical distribution

Headquarters

HQ city

Laval

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Products: Pro Doc Ltée generates revenue through the sale of generic prescription medications to community pharmacies. The company offers nearly 300 generic drug products covering various therapeutic categories including cardiovascular, neurological, metabolic, and anti-infective medications. Generic drugs are sold at lower prices than original brand-name drugs while maintaining equivalent therapeutic efficacy.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

Pro Doc Ltée manufactures and distributes nearly 300 generic prescription pharmaceutical products to community pharmacies, primarily in Quebec. The portfolio spans cardiovascular, neurological, metabolic, anti-infective, and gastrointestinal therapeutic categories, offering bioequivalent alternatives to brand-name medications at lower prices. Products are sold under both branded (PRO- prefixed) and unbranded generic formulations, with regulatory approval from Health Canada.

Product overview

Pro Doc Ltée is a Quebec-based generic pharmaceutical manufacturer serving Canadian community pharmacies since 1955, now part of the METRO pharmacy division. The company offers approximately 300 generic prescription drug products, including cardiovascular medications (anticoagulants like apixaban, rivaroxaban, edoxaban; statins; calcium channel blockers; ACE inhibitors), CNS medications (anticonvulsants, antidepressants, antipsychotics), antibiotics (amoxicillin, fluoroquinolones), diabetes treatments (metformin, sitagliptin), and gastrointestinal drugs (proton pump inhibitors). Products are distributed through an authenticated healthcare professional portal and include patient-facing French and English information leaflets. The portfolio features branded variants prefixed with 'PRO-' alongside unbranded generic formulations.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Prescription Pharmaceutical Portfolio (~300 products) A portfolio of nearly 300 generic prescription medications spanning therapeutic categories including antibiotics (amoxicillin, amoxicillin-clavulanate), cardiovascular agents (amlodipine, statins, anticoagulants such as apixaban, rivaroxaban, edoxaban), antidiabetics (metformin), neuropathic pain agents (pregabalin, gabapentin), and proton pump inhibitors (omeprazole, lansoprazole). Sold to community pharmacies as bioequivalent alternatives to brand-name drugs.
• Professional Healthcare Portal Authenticated web portal for Canadian healthcare professionals to access product information, requiring professional license verification, practice permit number, and provincial practice location.
• Consumer Information Leaflets (Feuillets d'informations) PDF patient information leaflets for all Pro Doc generic medications, available in French and English, providing dosage, usage, and safety information for patients.
• Pharmacovigilance Services Adverse drug reaction reporting system allowing healthcare professionals and consumers to report side effects, with regulatory reporting to Health Canada.

Quantifiable outcome

• Generic drugs sold at lower prices than brand-name alternatives due to reduced spending on medical representation and advertising
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• Groupe Jean Coutu (PJC) inc.coreStrategic or Co-development Partner · 1 January 2007Pro Doc Ltée became a subsidiary of Groupe Jean Coutu in 2007. Groupe Jean Coutu is a major retail pharmacy chain in Quebec, making Pro Doc an integral part of their pharmaceutical distribution and generic drug supply strategy.
• METRO Inc. (Pharmacy Division)coreStrategic or Co-development PartnerPro Doc Ltée is now part of the METRO pharmacy division, which groups together the Jean Coutu and Brunet pharmacy brands. This integration under METRO Inc. provides expanded distribution channels and synergies across Quebec's pharmacy retail sector.
• Santé Canada (Health Canada)OthersPro Doc Ltée products are subject to approval by Health Canada, which evaluates generic drugs for safety, efficacy, and quality. The evaluation process takes 2-5 years and ensures products meet the same standards as original medications.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Laboratoire Riva: Laboratoire Riva is a Quebec-based privately-held Canadian generic pharmaceutical manufacturer, geographically and operationally similar to Pro Doc, serving community pharmacies with a comparable generic product portfolio.
• Apotex Inc. Apotex is Canada's largest generic pharmaceutical manufacturer, producing a broad portfolio of generic prescription drugs. It is the most direct competitor to Pro Doc in the Canadian generic market, serving the same community pharmacy channel with overlapping therapeutic categories.
• Pharmascience Inc. Pharmascience is a Montreal-based privately-held generic pharmaceutical manufacturer with a comparable portfolio of generic prescription products distributed to Canadian pharmacies. Geographic proximity (Quebec) and similar product breadth make it a close direct peer.
• AA Pharma: AA Pharma is a Canadian specialty generic pharmaceutical company that develops, manufactures, and markets generic prescription drugs. It is a direct peer competing in the Canadian community pharmacy channel.
• Sanis Health: Sanis Health is a Canadian-based generic pharmaceutical company offering a broad range of generic prescription medications. It serves the same community pharmacy channel and competes in overlapping therapeutic categories.
• Apotex — focused on retail generics in Canada: Directly comparable generic manufacturer competing on price and therapeutic breadth within the same community pharmacy channel.
• Jamp Pharma: Jamp Pharma is a Canadian generic pharmaceutical manufacturer offering a wide range of generic prescription products. It is a direct competitor in the Canadian community pharmacy channel, with a similar value proposition on price and quality.

Broad incumbents

• Sandoz Canada: Sandoz is the generic pharmaceuticals division of Novartis and a major player in the Canadian generic market. It competes with Pro Doc in generic prescription products distributed through community pharmacies, with a broader global portfolio.
• Teva Canada: Teva Canada is the Canadian arm of Teva Pharmaceutical Industries, one of the world's largest generic manufacturers. It competes with Pro Doc across multiple therapeutic categories in the Canadian generic prescription market and is a major incumbent in the same channel.
• Mylan Pharmaceuticals ULC (Viatris): Viatris (formerly Mylan) is a global generics and specialty pharmaceutical company with a Canadian presence. It competes with Pro Doc in generic prescription categories distributed to community pharmacies across Canada.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pro-doc-ltée

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pro Doc Ltée